Exact Sciences Should Give Abbott's Diagnostics Business a Needed Boost -- Market Talk
Dow Jones
Nov 20, 2025
0929 ET - Abbott's acquisition of Exact Sciences could help revitalize Abbott's diagnostics business, TD Cowen analyst Joshua Jennings said in a report issued shortly before the deal was formerly announced earlier today. Jennings believes integrating Exact would add roughly 2.5 percentage points of incremental organic growth to Abbott's diagnostics segment during the early post-deal period, "essentially restoring the franchise to its historical baseline before pandemic distortions emerged." The acquisition would also likely provide a roughly 50 basis point boost to the entire company's organic revenue growth, a meaningful acceleration for a company of Abbott's scale. (nicholas.miller@wsj.com)
(END) Dow Jones Newswires
November 20, 2025 09:30 ET (14:30 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.